Work

Evaluation neuer molekularer Ansätze für die Behandlung der Fibrose

Year: 2013
Type: dissertation
Abstract: The underlying pathology of systemic fibrotic diseases such as chronic graft-versus-host disease (cGvHD) and systemic sclerosis (SSc) still remains unknown. Fibrotic diseases are characterized by persistently activated fibroblasts that release excessive amounts of extracellular matrix proteins. The accumulation of extracellular matrix results in disruption of the physiological tissue architecture and subsequent dysfunction of affected organs. As molecular mechanisms underlying in fibrotic disorders have only partially been revealed, and molecular targeted therapies are not yet established for clinical use, the aim of this thesis was to investigate new potential molecular targets in the treatment of tissue fibrosis. In the first part of the thesis we examined the effects of the combined inhibition of the abelson kinase (c-Abl) and platelet-derived growth factor receptors (PDGFR) in experimental sclerodermatous cGvHD. Treatment with imatinib or nilotinib abolished the aberrant activation of c-Abl and PDGFR and protected against experimental cGvHD. Preventive therapy with imatinib or nilotinib inhibited the development of sclerodermatous cGvHD. Clinical features such as weight loss, alopecia and skin ulcers as well as histological features with dermal thickening and accumulation of collagen were significantly reduced in mice treated with imatinib or nilotinib, but not in prednisone treated mice. Of note, imatinib and nilotinib were also effective for the treatment experimental cGvHD, when it has already been clinically manifest. In the second part of the thesis we could demonstrate that hedgehog signaling was activated in human and murine cGvHD with increased expression of sonic hedgehog and accumulation of the transcription factors Gli-1 and Gli-2. Treatment with LDE223, a highly selective small molecule antagonist of the hedgehog co-receptor Smoothened (Smo), abrogated the activation of hedgehog signaling and protected against experimental cGvHD. Preventive therapy with LDE223 almost completely impeded the development of clinical and histological features of sclerodermatous cGvHD. Treatment with LDE223 was also effective, when initiated after the onset of clinical manifestations of cGvHD. Hedgehog signaling stimulated the release of collagen from cultured fibroblasts, but did not affect leukocyte influx in murine cGvHD suggesting direct, leukocyte-independent stimulatory effects on fibroblasts as the pathomechanism of hedgehog signaling in cGvHD. In the last part of the thesis we investigated the role of JunD, a member of the AP-1 family of transcription factors, as a downstream mediator of TGF-β signaling in SSc. We showed that JunD was overexpressed in SSc skin and in cultured fibroblasts in a TGF-β dependent manner. The expression of JunD co-localized with pSmad 3 in fibrotic skin and silencing of Smad 3 or Smad 4 by siRNA prevented the induction of JunD by TGF-β. JunD-/- fibroblasts were less responsive to TGF-β and released less collagen upon stimulation with TGF-β. Moreover, JunD-/- mice were protected from bleomycin induced fibrosis with reduced dermal thickening, decreased myofibroblast counts and lower collagen content of lesional skin. The findings of the present thesis might have translational implication and stimulate novel therapeutic approaches, because inhibitors of c-Abl and PDGFR and hedgehog signaling are already in clinical trials for other diseases and AP-1 inhibitors are currently in clinical trials.
Language: German
Subfield: Rheumatology
Field: Medicine
Open Access status: green
OpenAlex ID: W7009748465
Cites: 139
Cited by:
Related to: 9